Catheter Precision (VTAK) announced that its 82% owned subsidiary has acquired certain heart failure related assets of Cardionomic. As previously announced, Catheter Precision entered into a definitive agreement with an assignor of Cardionomic, Inc. in April. For several years Cardionomic had been developing a new therapy based upon novel technology for the treatment of acute decompensated heart failure, or ADHF, for which over 1 million Americans are hospitalized annually. Patients admitted for ADHF have high in-hospital morbidity, frequent rehospitalization and subsequent death. The CPNS System consists of electrical stimulation via a temporary catheter inserted in the pulmonary artery targeting the root cause of heart failure by stimulating the autonomic cardiac nerves to restore autonomic balance. The initial studies show positive results.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTAK:
- Catheter Precision announces clinical data about VIVO to be presented
- Catheter Precision to acquire assets of Cardionomic related to CPNS system
- Catheter Precision receives notice of first patent allowance in US for LockeT
- Catheter Precision reports Q4 revenue $149k
- Catheter Precision to share data on LockeT at upcoming conferences